Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.
|Articles|October 1, 2002
Long-term tretinoin use improves cellular atypia
Los Angeles - Dermatologists concerned that long-term topical tretinoin use might worsen epidermal cellular atypia can rest assured it does not, according to a study presented at the annual meeting of the Society for Investigational Dermatology. In fact, the treatment used commonly to rid patients of the fine lines and mottled discoloration of sun damage improves epidermal cellular atypia.
Advertisement
Advertisement
Related to this article
Dermatology Times is looking back on the top stories in dermatology from the month of October.
From “Botox in a bottle” to castor oil and face taping, Dermatology Times reviews the evidence behind 3 viral dermatology trends from October.
Dermatology PAs unpack 4 frightening skin care myths and trends, from sunscreen misinformation and citrus DIYs to overusing actives and beef tallow.
The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of October.
Clinician FAQ on remibrutinib's FDA approval in symptomatic dermographism: RemIND efficacy, mechanism, safety, and supporting CSU evidence.
Elevate-Derm Summer 2026 faculty share practical lessons on hair loss exams, PIH, geriatric dermatology, and managing cholesterol rises on JAK inhibitors.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Tildrakizumab for Active Psoriatic Arthritis
2
October Social Media Mythbusters: 3 Viral Beauty Claims, Debunked
3
Interpreting Scalp and Nail Efficacy Data for Psoriasis Biologics
4
A Patient's Psoriasis Journey: From Topicals to Biologic Therapy
5